# Efficacy and Safety of Repaglinide Combined With Insulin in Type 2 Diabetes

> **NCT01720303** · PHASE4 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 159 (actual)

## Conditions studied

- Diabetes
- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** repaglinide
- **DRUG:** isophane human insulin
- **DRUG:** insulin

## Key facts

- **NCT ID:** NCT01720303
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-09-19
- **Primary completion:** 2003-04-10
- **Final completion:** 2003-04-10
- **Target enrollment:** 159 (ACTUAL)
- **Last updated:** 2017-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01720303

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01720303, "Efficacy and Safety of Repaglinide Combined With Insulin in Type 2 Diabetes". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01720303. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*